OT:***TSET NEWS***
BioPulse Inc. and TSET Inc. Pen Letter of Intent to Introduce IHT To the Peoples Republic of China
December 9, 1999 06:46 PM Eastern Time
SALT LAKE CITY, Dec. 9 /PRNewswire/ -- BioPulse International, Inc. BIOP announced today that it has received and ratified a Letter of Intent from TSET TSET to explore and develop the BioPulse cancer treatment modality in the Peoples Republic of China.
Operating in a number of global markets, TSET's original focus was exploiting certain business opportunities thought to be available in the People's Republic of China. Through its efforts with client company Computerized Thermal Imaging, Inc. ("CTI") in the development of the Chinese market for CTI's thermal imaging diagnostic systems, TSET has established relationships which both BioPulse and TSET believe will be valuable in connection with the joint study.
The BioPulse cancer treatment modality, referred to as "Insulin-induced Hypoglycemic Therapy, or "IHT, "utilizes the intravenous introduction of insulin in order to substantially lower blood sugar levels, thereby inducing a carefully-supervised hypoglycemic condition which specifically targets and destroys cancer cells while leaving healthy cells unharmed, all with no adverse side effects. Although insulin therapy has been used for many years to treat other medical conditions, use of the IHT modality for the treatment of cancer has been limited. BioPulse's use of IHT, together with a comprehensive detoxification and fortification program and nutritional and lifestyle education, creates an integrated "systemic" approach to the treatment of cancer which BioPulse believes is reliable and effective and of significant merit and value.
Both Companies intend that the Joint Study also include an examination of the Chinese legal and regulatory environment relating to cancer therapies, practices, and procedures and the means by which any required approvals may be obtained.
A spokesman for BioPulse said, "This could be quite a significant development. IHT lends itself to application in environments where there might not be fully developed medical infrastructures, and we believe that describes a vast number of potential modality sites in China."
BioPulse International, Inc., is a biotech company that provides clinical alternative medicine treatment programs. Each BioPulse clinic offers a comprehensive alternative medicine program that focuses on cancer, hepatitis C, lupus, lyme disease, and other degenerative diseases. In addition to developing its own regimens, BioPulse continually researches other treatments found throughout the world. The company works towards ensuring that its patients enjoy the most effective treatments available anywhere.
For complete information about the company, its alternative cancer therapies, and how to contact the company's corporate offices or its clinics, visit its website at www.biopulse.com or contact Jonathan Neville, president, BioPulse, Inc., 801-523-8838.
Reader's Caution: Statements contained in this press release are based on information provided solely by the company and are believed to be reliable. The statements are not to be construed as investment advice. The Publisher has been retained by the company to produce this release and no independent verification or analysis of the company has been made by the Publisher as to the financial condition, business, or other factors of the company. This release may contain forward-looking statements within the meaning of the private securities litigation reform act of 1995, such as expectations regarding the planned dates for commencement of proposed projects and the scope of those projects. Such forward-looking statements are inherently uncertain, and the actual results may differ from management's expectations. These uncertainties may include, without limitation, continued acceptance of the company's products and services, increased levels of competition, competitive new products and technological changes, and the company's dependence upon financing, third-party suppliers, and intellectual property rights. Further information on potential factors which could affect the financial condition and results of operations of the company may be detailed from time to time in the company's federal filings, annual report, offering memorandum, or prospectus.
SOURCE BioPulse International, Inc.
|
